

# Dongyun Yang

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7533307/dongyun-yang-publications-by-citations.pdf>  
**Version:** 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

198 papers	6,277 citations	42 h-index	73 g-index
204 ext. papers	7,140 ext. citations	4.7 avg, IF	5 L-index

#	Paper	IF	Citations
198	Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 76-82	2.2	462
197	FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3712-8	2.2	407
196	Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 2038-49	7.5	306
195	Primary tumor location as a prognostic factor in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	298
194	Molecular determinants of cetuximab efficacy. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3536-44	2.2	205
193	Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 1833-41	8.7	197
192	Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 7554-63	12.9	163
191	Gender disparities in metastatic colorectal cancer survival. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 6391-7	12.9	135
190	Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>Haematologica</i> , <b>2018</b> , 103, e404-e407	6.6	131
189	Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. <i>Journal of Gastrointestinal Oncology</i> , <b>2011</b> , 2, 77-84	2.8	121
188	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 1921-8	8.7	111
187	A let-7 microRNA-binding site polymorphism in 3' untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. <i>Annals of Oncology</i> , <b>2011</b> , 22, 104-109	10.3	109
186	Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 7884-95	12.9	102
185	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. <i>Nature Medicine</i> , <b>2011</b> , 17, 715-9	50.5	101
184	Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1734-41	10.3	100
183	Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 475-83	1.9	90
182	Generation of a concise gene panel for outcome prediction in urinary bladder cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3929-37	2.2	89

181	Influence of sex on the survival of patients with esophageal cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2265-72	2.2	85
180	Common cancer stem cell gene variants predict colon cancer recurrence. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6934-43	12.9	84
179	Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis. <i>Cancer</i> , <b>2014</b> , 120, 3707-16	6.4	80
178	The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 1353-64	6.1	79
177	Piecewise growth curve modeling approach for longitudinal prevention study. <i>Computational Statistics and Data Analysis</i> , <b>2004</b> , 46, 213-225	1.6	72
176	Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. <i>British Journal of Haematology</i> , <b>2012</b> , 158, 91-8	4.5	69
175	Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5783-92	12.9	67
174	9-cis retinoic acid promotes lymphangiogenesis and enhances lymphatic vessel regeneration: therapeutic implications of 9-cis retinoic acid for secondary lymphedema. <i>Circulation</i> , <b>2012</b> , 125, 872-82	16.7	65
173	Physical activity and breast cancer risk among Asian-American women in Los Angeles: a case-control study. <i>Cancer</i> , <b>2003</b> , 97, 2565-75	6.4	60
172	Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 3037-42	10.1	57
171	Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3726-31	2.2	56
170	Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. <i>Molecular Cancer Therapeutics</i> , <b>2004</b> , 3, 499-511	6.1	56
169	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. <i>PLoS ONE</i> , <b>2013</b> , 8, e66774	3.7	55
168	Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2163-9	2.2	54
167	Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2005</b> , 5, 124-31	3.8	54
166	Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei, China. <i>Carcinogenesis</i> , <b>2007</b> , 28, 1437-41	4.6	52
165	Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. <i>Pharmacogenomics</i> , <b>2006</b> , 7, 67-88	2.6	51
164	Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. <i>Pharmacogenomics</i> , <b>2007</b> , 8, 1705-13	2.6	50

163	Molecular determinants of irinotecan efficacy. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 2435-42	7.5	50
162	Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3469-77	12.9	48
161	Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 161-8	1.9	48
160	The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survival. <i>Gynecologic Oncology</i> , <b>2013</b> , 128, 552-9	4.9	46
159	A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4499-4510	12.9	44
158	A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 65, 979-88	3.5	44
157	Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 265-269	4.7	44
156	EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5161-9	12.9	39
155	Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 95-102	1.9	39
154	Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5591-602	12.9	38
153	Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. <i>Pharmacogenomics Journal</i> , <b>2015</b> , 15, 354-62	3.5	36
152	Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. <i>Annals of Oncology</i> , <b>2010</b> , 21, 78-86	10.3	36
151	A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1175-83	4.3	33
150	Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. <i>Pharmacogenomics Journal</i> , <b>2013</b> , 13, 173-80	3.5	32
149	Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. <i>Annals of Surgery</i> , <b>2010</b> , 251, 857-64	7.8	32
148	ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. <i>Drug Metabolism Letters</i> , <b>2007</b> , 1, 23-30	2.1	31
147	MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. <i>Blood Advances</i> , <b>2019</b> , 3, 83-95	7.8	27
146	Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 528-39	6.1	27

145	Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. <i>International Journal of Cancer</i> , <b>2011</b> , 129, 1096-104	7.5	27
144	Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 3363-8	12.9	27
143	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 514-520	4.7	27
142	Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E253-E255	7.1	26
141	Association of common gene variants in the WNT/βcatenin pathway with colon cancer recurrence. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 142-50	3.5	26
140	Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 29-34	3.5	25
139	Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 28-34	3.5	25
138	Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , <b>2015</b> , 15, 69-76	3.5	24
137	Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. <i>Blood Advances</i> , <b>2018</b> , 2, 1756-1764	7.8	23
136	Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. <i>Clinical Colorectal Cancer</i> , <b>2013</b> , 12, 275-9	3.8	22
135	Molecular determinants in targeted therapy for esophageal adenocarcinoma. <i>Archives of Surgery</i> , <b>2006</b> , 141, 476-81; discussion 481-2		22
134	Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. <i>Archives of Surgery</i> , <b>2004</b> , 139, 712-6; discussion 716-7		22
133	Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2401-8	6.1	21
132	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , <b>2020</b> , 4, 2073-2083	7.8	21
131	Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , <b>2011</b> , 11, 93-9	3.5	21
130	Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1015-1022	10.3	20
129	Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 332-9	10.3	20
128	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2450-6	10.3	20

127	Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 578-85	2	20
126	Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes. <i>Cancer Medicine</i> , <b>2018</b> , 7, 499-507	4.8	20
125	Outcome disparities among ethnic subgroups of Waldenström's macroglobulinemia: a population-based study. <i>Oncology</i> , <b>2014</b> , 86, 253-62	3.6	20
124	Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2006</b> , 7, 332-7	4.9	20
123	Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 105, 1025-1033	4	19
122	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2780-2785	10.3	19
121	GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2431-2439	10.3	19
120	Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women. <i>Breast Cancer Research and Treatment</i> , <b>2002</b> , 72, 139-43	4.4	19
119	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, e322-e327	4.7	19
118	Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 214-8	3.8	18
117	Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 555-63	1.9	18
116	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , <b>2015</b> , 64, 921-8	19.2	17
115	Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1518-1524	8.7	17
114	Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 2261-72	6.1	17
113	Cell cycle regulators are critical for maintaining the differentiation potential and immaturity in adipogenesis of adipose-derived stem cells. <i>Differentiation</i> , <b>2011</b> , 82, 136-43	3.5	17
112	Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. <i>Pharmacogenomics</i> , <b>2011</b> , 12, 27-39	2.6	17
111	Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2017</b> , 86, 197-206	7.5	16
110	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e395-e414	3.8	16



109	Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis. <i>Cancer</i> , <b>2016</b> , 122, 618-25	6.4	16
108	Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3218-26	12.9	16
107	Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e741-e749	3.8	16
106	Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. <i>Oncotarget</i> , <b>2016</b> , 7, 53668-53678	3.3	16
105	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , <b>2017</b> , 77, 13-20	7.5	15
104	The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 130-4	3.5	15
103	Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. <i>International Journal of Cancer</i> , <b>2017</b> , 141, 1222-1230	7.5	14
102	Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. <i>Pharmacogenomics Journal</i> , <b>2015</b> , 15, 226-34	3.5	14
101	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 784-793	12.9	14
100	Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups. <i>Blood Cancer Journal</i> , <b>2014</b> , 4, e243	7	13
99	Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. <i>Journal of Hematology and Oncology</i> , <b>2009</b> , 2, 30	22.4	13
98	AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. <i>Prostate</i> , <b>2016</b> , 76, 597-608	4.2	13
97	Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 751-9	4.6	13
96	Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). <i>Pharmacogenomics Journal</i> , <b>2013</b> , 13, 410-6	3.5	12
95	Trends in colorectal cancer mortality in hispanics: a SEER analysis. <i>Oncotarget</i> , <b>2017</b> , 8, 108771-108777	3.3	12
94	Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. <i>Pharmacogenomics Journal</i> , <b>2016</b> , 16, 312-9	3.5	11
93	Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer. <i>Pharmacogenetics and Genomics</i> , <b>2015</b> , 25, 30-7	1.9	11
92	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1084-1090	4.7	11

91	CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 232-7	7.5	11
90	Gender-related survival differences associated with polymorphic variants of estrogen receptor- $\beta$ (ER $\beta$ ) in patients with metastatic colon cancer. <i>Pharmacogenomics Journal</i> , <b>2011</b> , 11, 375-82	3.5	11
89	Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 135-41	3.5	10
88	Prospective study of EGFR intron 1 (CA) <sub>n</sub> repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 322-7	3.5	10
87	Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 305-11	3.8	10
86	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 1622-1625	4.7	9
85	CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. <i>Pharmacogenomics Journal</i> , <b>2017</b> , 17, 543-550	3.5	9
84	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. <i>Cancer</i> , <b>2015</b> , 121, 1898-905	6.4	9
83	Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 473-475	4.4	9
82	Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer. <i>Pharmacogenomics Journal</i> , <b>2017</b> , 17, 36-41	3.5	8
81	TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1405-11	6.1	8
80	Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. <i>Pharmacogenomics Journal</i> , <b>2015</b> , 15, 521-9	3.5	8
79	Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 588-96	1.9	8
78	The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1455-64	10.3	8
77	Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery. <i>Journal of Neurosurgery</i> , <b>2016</b> , 125, 31-39	3.2	8
76	Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. <i>Pharmacogenomics Journal</i> , <b>2017</b> , 17, 528-534	3.5	7
75	The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era - a surveillance, epidemiology, and end results database analysis. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 618-626	4.5	7
74	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1740-5	6.1	7



73	Drug abuse prevention program development. Results among Latino and non-Latino white adolescents. <i>Evaluation and the Health Professions</i> , <b>2003</b> , 26, 355-79	2.5	7
72	Gene expression profiles and tumor locations in colorectal cancer (left vs. right vs. rectum).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3527-3527	2.2	7
71	Genetic variants associated with colorectal brain metastases susceptibility and survival. <i>Pharmacogenomics Journal</i> , <b>2017</b> , 17, 29-35	3.5	6
70	Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1728-33	10.3	6
69	Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 2814-2821	6.1	6
68	Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. <i>Clinical Colorectal Cancer</i> , <b>2016</b> , 15, e221-e227	3.8	6
67	Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 877-883	4.4	6
66	Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. <i>International Journal of Cancer</i> , <b>2017</b> , 141, 383-392	7.5	5
65	Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. <i>Cancer Science</i> , <b>2020</b> , 111, 441-450	6.9	5
64	A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 2251-8	6.1	5
63	RBC and platelet transfusion support in the first 30 and 100 days after haploidentical hematopoietic stem cell transplantation. <i>Transfusion</i> , <b>2019</b> , 59, 3371-3385	2.9	5
62	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. <i>European Journal of Cancer</i> , <b>2019</b> , 107, 100-114	7.5	5
61	Patient-reported outcomes of the relative severity of side effects from cancer radiotherapy. <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 309-316	3.9	5
60	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 2000-2008	4.7	5
59	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e471-e488	3.8	4
58	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 623-632	3.5	4
57	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , <b>2017</b> , 123, 4506-4514	6.4	4
56	An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence. <i>Pharmacogenomics Journal</i> , <b>2013</b> , 13, 342-8	3.5	4

55	Ethnic gene profile of genes involved in angiogenesis to predict regional bevacizumab efficacy difference in gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4026-4026	2.2	4
54	LMTK3 polymorphism in patients with metastatic colon cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 471-471	2.2	4
53	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e400-e405	2	3
52	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2374-81	6.1	3
51	Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1697-1703	4.7	3
50	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , <b>2020</b> , 131, 89-97	7.5	3
49	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. <i>PLoS ONE</i> , <b>2018</b> , 13, e0193640	3.7	3
48	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. <i>Cancer</i> , <b>2019</b> , 125, 3853-3863	6.4	3
47	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. <i>PLoS ONE</i> , <b>2020</b> , 15, e0239439	3.7	3
46	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
45	Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 262-269	3.5	2
44	Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 539-47	1.9	2
43	A SNAKE VENOM DISINTEGRIN WITH POTENT ANTITUMOR AND ANTIANGIOGENIC ACTIVITY. <i>Toxin Reviews</i> , <b>2005</b> , 24, 113-142	2.3	2
42	Secondary Acute Lymphoblastic Leukemia after Primary Solid Organ Malignancy: A SEER Analysis of Incidence and Outcomes. <i>Blood</i> , <b>2014</b> , 124, 935-935	2.2	2
41	Persistent Racial/Ethnic Disparities in Outcomes for Multiple Myeloma: A SEER-Database Update. <i>Blood</i> , <b>2016</b> , 128, 1191-1191	2.2	2
40	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide: CRS post haploidentical HCT with PTCy. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> ,		2
39	Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant. <i>Transfusion</i> , <b>2020</b> , 60, 2225-2242	2.9	2
38	Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 2567-2577	7.5	2

37	Long-Term Follow-up of High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Children and Young Adults with Metastatic or Relapsed Ewing Sarcoma: A Single-Institution Experience. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 72.e1-72.e7		2
36	Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ER-positive advanced breast cancer. <i>Pharmacogenomics Journal</i> , <b>2015</b> , 15, 235-40	3.5	1
35	A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 43-48	3.5	1
34	The Cancer Bell: Too Much of a Good Thing?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 105, 247-253	4	1
33	Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2020</b> , 136, 41-42	2.2	1
32	A Machine-Learning Sepsis Prediction Model for Patients Undergoing Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2018</b> , 132, 711-711	2.2	1
31	Racial/Ethnic Disparities in NK/T-Cell Non-Hodgkin Lymphomas in the US: A SEER Analysis. <i>Blood</i> , <b>2016</b> , 128, 3612-3612	2.2	1
30	Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3518-3518	2.2	1
29	mRNA expression levels of candidate genes and clinical outcome in mCRC patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3640-3640	2.2	1
28	Immune-related genes to predict clinical outcome of cetuximab (cet) treatment for metastatic colorectal cancer (mCRC): Immuno-Oncology assay research.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1159 <sup>2,2</sup> -1159 <sup>1</sup>		
27	Genetic variations within the vitamin C transporter genes to predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11507-11507	2.2	1
26	Association of immune-related genes to neutrophil-lymphocyte ratio (NLR) with survival of cetuximab treatment for metastatic colorectal cancer (mCRC): JACCRO CC-05/06AR.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11613-11613	2.2	1
25	Gastric Cancer Among Asian Americans <b>2016</b> , 249-269		1
24	Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3585-3585	2.2	1
23	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 255.e1-255.e9		1
22	Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 851-858	3.8	1
21	High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.. <i>American Journal of Hematology</i> , <b>2022</b> ,	7.1	0
20	Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant Recipients: ESPRIT). <i>Blood</i> , <b>2019</b> , 134, 4477-4477	2.2	0

19	Ethnic Disparities in Chronic Lymphocytic Leukemia Survival: A SEER Database Review. <i>Blood</i> , <b>2012</b> , 120, 757-757	2.2	O
18	Ethnic Disparities and Their Association With Outcomes In Chronic Myeloid Leukemia. <i>Blood</i> , <b>2013</b> , 122, 2917-2917	2.2	O
17	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , <b>2021</b> , 11, 12191	4.9	O
16	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 125	7	O
15	Reply to J. Zhang et al. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 816-7	2.2	
14	Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis. <i>Blood</i> , <b>2020</b> , 136, 21-22	2.2	
13	Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide. <i>Blood</i> , <b>2020</b> , 136, 10-11	2.2	
12	Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization. <i>Blood</i> , <b>2020</b> , 136, 16-17	2.2	
11	A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2021</b> , 138, 334-334	2.2	
10	Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , <b>2021</b> ,	4.4	
9	Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 1549-1549	2.2	
8	Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience. <i>Blood</i> , <b>2018</b> , 132, 3386-3386	2.2	
7	Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation. <i>Blood</i> , <b>2018</b> , 132, 2181-2181	2.2	
6	Outcome Disparities In Waldenstrom's Macroglobulinemia: A SEER Database Analysis. <i>Blood</i> , <b>2011</b> , 118, 845-845	2.2	
5	Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-7	1.9	
4	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer <b>2020</b> , 15, e0239439		
3	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer <b>2020</b> , 15, e0239439		
2	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer <b>2020</b> , 15, e0239439		

- 1 A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer **2020**, 15, e0239439